Bionano Genomics, Inc. (BNGO)
| Previous close | 0.8831 |
| Open | 0.8886 |
| Bid | 0.9203 x 100 |
| Ask | 0.9698 x 100 |
| Day's range | 0.8863 - 0.9800 |
| 52-week range | 0.7100 - 8.2000 |
| Volume | |
| Avg. volume | 1,486,808 |
| Market cap | 59.118M |
| Beta (5Y monthly) | 2.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.8100 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.67 |
GlobeNewswireBionano to Report First Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 8, 2024
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, May 8th, 2024Time:4:30 p.m. ETParticipant Dial-In:Toll Free: 1-833-630-1956International: 1-412-317-1837Webcast Link:https://edge.media-server.com/
- GlobeNewswire
Bionano to Present at the RBC Capital Markets 2024 Global Healthcare Conference
SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the RBC Capital Markets 2024 Global Healthcare Conference on May 15, 2024. Conference & Webcast Details Date:May 15, 2024Time:8:00 a.m. to 8:25 a.m. ETPresenter:Erik Holmlin, PhD, CEO of BionanoWebcast:Link to Register A replay / recording of the session will be available following the conference through the B
- GlobeNewswire
Bionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the results of an implementation study conducted by researchers at University Medical Center Groningen that compared optical genome mapping (OGM) to traditional cytogenetic methods for the detection of structural variants (SVs) in bone marrow aspirate (BMA) samples. OGM has been shown to regularly detect SVs missed by other methods, as a result of the higher resolution and sensitivity of OGM. Som
